Loading…
Suzhou-based Chinese biopharmaceutical company, per its industry classification; specific pipeline not independently confirmed.
Suzhou-based Chinese biopharmaceutical company, per its industry classification; specific pipeline not independently confirmed.
Moat: none
Headquarters: Suzhou, China · Employees: 85
Size LongBio Pharma (Suzhou) (1779.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $554M, the 733rd largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$56.95 on 6 Nov 2026.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | HK$0 | HK$0 | HK$0 | HK$0 |
| Revenue growth | — | — | — | — |
| Gross profit | -HK$8.86M | -HK$8.83M | -HK$7.86M | -HK$6.20M |
| EBITDA | -HK$234M | -HK$167M | -HK$111M | -HK$83.8M |
| Net income | -HK$243M | -HK$190M | -HK$149M | -HK$106M |
| Free cash flow | n/a | -HK$137M | -HK$118M | -HK$70.0M |
| Capital expenditure | n/a | HK$4.76M | HK$6.66M | HK$2.73M |
| Total debt | n/a | HK$42.2M | HK$476M | HK$347M |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1779.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -41.9% | -13.3% | 2nd lowest of 21 |
| Distance from 52-week high | -65.7% | -46.8% | 3rd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $554M | n/a | n/a | n/a | n/a | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $553M | -19% | +6% | -11% | 6.5× | n/a | n/a |
| Faeth Therapeutics FTH | United States | $570M | -6% | n/a | n/a | n/a | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $537M | -14% | -17% | 0% | 7.0× | 31.6% | +7.0% |
| Valneva VLA.PA | France | $534M | -2% | -27% | -87% | 4.0× | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $576M | n/a | +674% | -495% | 25.7× | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $531M | -33% | +2% | 17% | 2.2× | n/a | n/a |
| Liaoning Dingjide Petrochemical 603255.SS | China | $530M | -15% | +70% | 5% | 5.4× | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $526M | -25% | +4% | 8% | 8.0× | n/a | n/a |
| Climb Bio CLYM | United States | $591M | -10% | n/a | n/a | n/a | n/a | n/a |
| Genfit GNFT.PA | France | $593M | +19% | +28% | -130% | 11.2× | 40.0% | +143.5% |
| HanchorBio 7827.TW | Taiwan | $511M | n/a | n/a | -225% | 48.0× | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $507M | -11% | -1% | 26% | 13.7× | n/a | n/a |
| Neurogene NGNE | United States | $506M | -18% | -100% | n/a | n/a | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $505M | +48% | n/a | n/a | n/a | n/a | n/a |
| Ascletis Pharma 1672.HK | Hong Kong | $610M | -73% | -59% | -71,976% | 2,088.7× | n/a | n/a |
| Berry Genomics 000710.SZ | China | $504M | -5% | -2% | -24% | 3.8× | n/a | n/a |
| Qurient 115180.KS | South Korea | $503M | -59% | -20% | -517% | 98.9× | n/a | n/a |
| Crescent Biopharma CBIO | United States | $503M | -28% | n/a | -1,418% | 28.3× | n/a | n/a |
| Apnimed APMD | United States | $629M | n/a | +380% | -140% | 20.3× | n/a | n/a |
| Geron GERN | United States | $636M | -29% | +19% | -8% | 1.6× | n/a | n/a |